|
|
 Previous Article | Table of Contents | Next Article 
Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein
kinase activation in multiple myeloma cells
D Chauhan, S Kharbanda, A Ogata, M Urashima, G Teoh, M Robertson, DW Kufe and KC Anderson
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston,
MA 02115, USA.
Fas belongs to the family of type-1 membrane proteins that transduce
apoptotic signals. In the present studies, we characterized signaling
during Fas-induced apoptosis in RPMI-8226 and IM-9 multiple myeloma (MM)
derived cell lines as well as patient plasma cell leukemia cells. Treatment
with anti-Fas (7C11) monoclonal antibody (MoAb) induced apoptosis,
evidenced by internucleosomal DNA fragmentation and propidium iodide
staining, and was associated with increased expression of c-jun early
response gene. We also show that anti-Fas MoAb treatment is associated with
activation of stress-activated protein kinase (SAPK) and p38
mitogen-activated protein kinase (MAPK); however, no detectable increase in
extracellular signal-regulated kinases (ERK1 and ERK2) activity was
observed. Because interleukin-6 (IL-6) is a growth factor for MM cells and
inhibits apoptosis induced by dexamethasone and serum starvation, we
examined whether IL-6 affects anti-Fas MoAb-induced apoptosis and
activation of SAPK or p38 MAPK in MM cells. Culture of MM cells with IL-6
before treatment with anti-Fas MoAb significantly reduced both DNA
fragmentation and activation of SAPK, without altering induction of p38
MAPK activity. These results therefore suggest that anti-Fas MoAb-induced
apoptosis in MM cells is associated with activation of SAPK, and that IL-6
may both inhibit apoptosis and modulate SAPK activity.
Volume 89,
Issue 1,
pp. 227-234,
01/01/1997
Copyright © 1997 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Fulciniti, T. Hideshima, C. Vermot-Desroches, S. Pozzi, P. Nanjappa, Z. Shen, N. Patel, E. S. Smith, W. Wang, R. Prabhala, et al.
A High-Affinity Fully Human Anti-IL-6 mAb, 1339, for the Treatment of Multiple Myeloma
Clin. Cancer Res.,
December 1, 2009;
15(23):
7144 - 7152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. H. Shain, D. N. Yarde, M. B. Meads, M. Huang, R. Jove, L. A. Hazlehurst, and W. S. Dalton
{beta}1 Integrin Adhesion Enhances IL-6-Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation
Cancer Res.,
February 1, 2009;
69(3):
1009 - 1015.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ara, L. Song, H. Shimada, N. Keshelava, H. V. Russell, L. S. Metelitsa, S. G. Groshen, R. C. Seeger, and Y. A. DeClerck
Interleukin-6 in the Bone Marrow Microenvironment Promotes the Growth and Survival of Neuroblastoma Cells
Cancer Res.,
January 1, 2009;
69(1):
329 - 337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sharma and A. Lichtenstein
Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors
Blood,
August 15, 2008;
112(4):
1338 - 1345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. Perez, N. Parquet, K. Shain, R. Nimmanapalli, M. Alsina, C. Anasetti, and W. Dalton
Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP
J. Immunol.,
February 1, 2008;
180(3):
1545 - 1555.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kiziltepe, T. Hideshima, K. Ishitsuka, E. M. Ocio, N. Raje, L. Catley, C.-Q. Li, L. J. Trudel, H. Yasui, S. Vallet, et al.
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells
Blood,
July 15, 2007;
110(2):
709 - 718.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kiziltepe, T. Hideshima, L. Catley, N. Raje, H. Yasui, N. Shiraishi, Y. Okawa, H. Ikeda, S. Vallet, S. Pozzi, et al.
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
Mol. Cancer Ther.,
June 1, 2007;
6(6):
1718 - 1727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, P. Neri, M. Velankar, K. Podar, T. Hideshima, M. Fulciniti, P. Tassone, N. Raje, C. Mitsiades, N. Mitsiades, et al.
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)
Blood,
February 1, 2007;
109(3):
1220 - 1227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, P. Neri, P. Tassone, H. Yasui, K. Ishitsuka, N. Raje, D. Chauhan, K. Podar, C. Mitsiades, L. Dang, et al.
MLN120B, a Novel I{kappa}B Kinase {beta} Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo.
Clin. Cancer Res.,
October 1, 2006;
12(19):
5887 - 5894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Li, S. Cortez, T. Nakamachi, V. Batuman, and A. Arimura
Pituitary Adenylate Cyclase-Activating Polypeptide Is a Potent Inhibitor of the Growth of Light Chain-Secreting Human Multiple Myeloma Cells.
Cancer Res.,
September 1, 2006;
66(17):
8796 - 8803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, L. Catley, H. Yasui, K. Ishitsuka, N. Raje, C. Mitsiades, K. Podar, N. C. Munshi, D. Chauhan, P. G. Richardson, et al.
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Blood,
May 15, 2006;
107(10):
4053 - 4062.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Karadag, M. Zhou, and P. I. Croucher
ADAM-9 (MDC-9/meltrin-{gamma}), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the {alpha}vbeta5 integrin
Blood,
April 15, 2006;
107(8):
3271 - 3278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Yan, P. Frost, Y. Shi, B. Hoang, S. Sharma, M. Fisher, J. Gera, and A. Lichtenstein
Mechanism by Which Mammalian Target of Rapamycin Inhibitors Sensitize Multiple Myeloma Cells to Dexamethasone-Induced Apoptosis
Cancer Res.,
February 15, 2006;
66(4):
2305 - 2313.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Meng, Y. Yamagiwa, S. Taffetani, J. Han, and T. Patel
IL-6 activates serum and glucocorticoid kinase via p38{alpha} mitogen-activated protein kinase pathway
Am J Physiol Cell Physiol,
October 1, 2005;
289(4):
C971 - C981.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Hodge, W. Xiao, B. Peng, J. C. Cherry, D. J. Munroe, and W. L. Farrar
Enforced Expression of Superoxide Dismutase 2/Manganese Superoxide Dismutase Disrupts Autocrine Interleukin-6 Stimulation in Human Multiple Myeloma Cells and Enhances Dexamethasone-Induced Apoptosis
Cancer Res.,
July 15, 2005;
65(14):
6255 - 6263.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Yasui, T. Hideshima, M. Hamasaki, A. M. Roccaro, N. Shiraishi, S. Kumar, P. Tassone, K. Ishitsuka, N. Raje, Y.-T. Tai, et al.
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma
Blood,
July 15, 2005;
106(2):
706 - 712.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hamasaki, T. Hideshima, P. Tassone, P. Neri, K. Ishitsuka, H. Yasui, N. Shiraishi, N. Raje, S. Kumar, D. H. Picker, et al.
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo
Blood,
June 1, 2005;
105(11):
4470 - 4476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Sohara, H. Shimada, C. Minkin, A. Erdreich-Epstein, J. A. Nolta, and Y. A. DeClerck
Bone Marrow Mesenchymal Stem Cells Provide an Alternate Pathway of Osteoclast Activation and Bone Destruction by Cancer Cells
Cancer Res.,
February 15, 2005;
65(4):
1129 - 1135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Abraham, K. V. Ballman, A. Dispenzieri, D. E. Grill, M. K. Manske, T. L. Price-Troska, N. G. Paz, M. A. Gertz, and R. Fonseca
Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis
Blood,
January 15, 2005;
105(2):
794 - 803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-M. Hui, W. Zhang, W. Chen, D. Xi, B. Purow, G. C. Friedman, and H. A. Fine
Agents with Selective Estrogen Receptor (ER) Modulator Activity Induce Apoptosis In vitro and In vivo in ER-Negative Glioma Cells
Cancer Res.,
December 15, 2004;
64(24):
9115 - 9123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Raje, S. Kumar, T. Hideshima, K. Ishitsuka, D. Chauhan, C. Mitsiades, K. Podar, S. Le Gouill, P. Richardson, N. C. Munshi, et al.
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
Blood,
December 15, 2004;
104(13):
4188 - 4193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Yuan, F. J. Liddle, S. Mahajan, and D. A. Frank
IL-6-induced survival of colorectal carcinoma cells is inhibited by butyrate through down-regulation of the IL-6 receptor
Carcinogenesis,
November 1, 2004;
25(11):
2247 - 2255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, G. Li, K. Podar, T. Hideshima, C. Mitsiades, R. Schlossman, N. Munshi, P. Richardson, F. E. Cotter, and K. C. Anderson
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells
Blood,
October 15, 2004;
104(8):
2458 - 2466.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson
Advances in biology of multiple myeloma: clinical applications
Blood,
August 1, 2004;
104(3):
607 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, G. Li, K. Podar, T. Hideshima, R. Shringarpure, L. Catley, C. Mitsiades, N. Munshi, Y. T. Tai, N. Suh, et al.
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance
Blood,
April 15, 2004;
103(8):
3158 - 3166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yaccoby, M. J. Wezeman, A. Henderson, M. Cottler-Fox, Q. Yi, B. Barlogie, and J. Epstein
Cancer and the Microenvironment: Myeloma-Osteoclast Interactions as a Model
Cancer Res.,
March 15, 2004;
64(6):
2016 - 2023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Yamagiwa, C. Marienfeld, F. Meng, M. Holcik, and T. Patel
Translational Regulation of X-Linked Inhibitor of Apoptosis Protein by Interleukin-6: A Novel Mechanism of Tumor Cell Survival
Cancer Res.,
February 15, 2004;
64(4):
1293 - 1298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Oskeritzian, W. Zhao, A. L. Pozez, N. M. Cohen, M. Grimes, and L. B. Schwartz
Neutralizing Endogenous IL-6 Renders Mast Cells of the MCT Type from Lung, but Not the MCTC Type from Skin and Lung, Susceptible to Human Recombinant IL-4-Induced Apoptosis
J. Immunol.,
January 1, 2004;
172(1):
593 - 600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, D. Chauhan, T. Hayashi, K. Podar, M. Akiyama, C. Mitsiades, N. MItsiades, B. Gong, L. Bonham, P. de Vries, et al.
Antitumor Activity of Lysophosphatidic Acid Acyltransferase-{beta} Inhibitors, a Novel Class of Agents, in Multiple Myeloma
Cancer Res.,
December 1, 2003;
63(23):
8428 - 8436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. H. Yang, M. H. Ma, R. A. Vescio, and J. R. Berenson
Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis
J. Clin. Oncol.,
November 15, 2003;
21(22):
4239 - 4247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, G. Li, T. Hideshima, K. Podar, C. Mitsiades, N. Mitsiades, L. Catley, Y. T. Tai, T. Hayashi, R. Shringarpure, et al.
Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance
Blood,
November 1, 2003;
102(9):
3379 - 3386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Greil, G. Anether, K. Johrer, and I. Tinhofer
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools
J. Leukoc. Biol.,
September 1, 2003;
74(3):
311 - 330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Platanias
Map kinase signaling pathways and hematologic malignancies
Blood,
June 15, 2003;
101(12):
4667 - 4679.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. H. Underhill, D. George, E. G. Bremer, and G. S. Kansas
Gene expression profiling reveals a highly specialized genetic program of plasma cells
Blood,
May 15, 2003;
101(10):
4013 - 4021.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, G. Li, D. Auclair, T. Hideshima, P. Richardson, K. Podar, N. Mitsiades, C. Mitsiades, C. Li, R. S. Kim, et al.
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays
Blood,
May 1, 2003;
101(9):
3606 - 3614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, M. Akiyama, T. Hayashi, P. Richardson, R. Schlossman, D. Chauhan, and K. C. Anderson
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu
Blood,
January 15, 2003;
101(2):
703 - 705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Dai, T. H. Landowski, S. T. Rosen, P. Dent, and S. Grant
Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism
Blood,
October 16, 2002;
100(9):
3333 - 3343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, L. Catley, T. Hideshima, G. Li, R. Leblanc, D. Gupta, M. Sattler, P. Richardson, R. L. Schlossman, K. Podar, et al.
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells
Blood,
August 28, 2002;
100(6):
2187 - 2194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. J. Spanswick, C. Craddock, M. Sekhar, P. Mahendra, P. Shankaranarayana, R. G. Hughes, D. Hochhauser, and J. A. Hartley
Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma
Blood,
June 17, 2002;
100(1):
224 - 229.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Greenstein, K. Ghias, N. L. Krett, and S. T. Rosen
Mechanisms of Glucocorticoid-mediated Apoptosis in Hematological Malignancies
Clin. Cancer Res.,
June 1, 2002;
8(6):
1681 - 1694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, D. Chauhan, P. Richardson, C. Mitsiades, N. Mitsiades, T. Hayashi, N. Munshi, L. Dang, A. Castro, V. Palombella, et al.
NF-kappa B as a Therapeutic Target in Multiple Myeloma
J. Biol. Chem.,
May 3, 2002;
277(19):
16639 - 16647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Anderson, J. D. Shaughnessy Jr., B. Barlogie, J.-L. Harousseau, and G. D. Roodman
Multiple Myeloma
Hematology,
January 1, 2002;
2002(1):
214 - 240.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M.-T. Lin, C.-Y. Juan, K.-J. Chang, W.-J. Chen, and M.-L. Kuo
IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1
Carcinogenesis,
December 1, 2001;
22(12):
1947 - 1953.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-h. Hsu, Y. Shi, S. Krajewski, S. Renner, M. Fisher, J. C. Reed, T. F. Franke, and A. Lichtenstein
The AKT kinase is activated in multiple myeloma tumor cells
Blood,
November 1, 2001;
98(9):
2853 - 2855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Mitsiades, S. P. Treon, N. Mitsiades, Y. Shima, P. Richardson, R. Schlossman, T. Hideshima, and K. C. Anderson
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
Blood,
August 1, 2001;
98(3):
795 - 804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Grad, N. J. Bahlis, I. Reis, M. M. Oshiro, W. S. Dalton, and L. H. Boise
Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells
Blood,
August 1, 2001;
98(3):
805 - 813.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Frassanito, A. Cusmai, G. Iodice, and F. Dammacco
Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis
Blood,
January 15, 2001;
97(2):
483 - 489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Hjertner, H. Hjorth-Hansen, M. Borset, C. Seidel, A. Waage, and A. Sundan
Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells
Blood,
January 15, 2001;
97(2):
516 - 522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Dalton, P. L. Bergsagel, W. M. Kuehl, K. C. Anderson, and J. L. Harousseau
Multiple Myeloma
Hematology,
January 1, 2001;
2001(1):
157 - 177.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Tu, A. Gardner, and A. Lichtenstein
The Phosphatidylinositol 3-Kinase/AKT Kinase Pathway in Multiple Myeloma Plasma Cells: Roles in Cytokine-dependent Survival and Proliferative Responses
Cancer Res.,
December 1, 2000;
60(23):
6763 - 6770.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. C. Rawstron, J. A. L. Fenton, J. Ashcroft, A. English, R. A. Jones, S. J. Richards, G. Pratt, R. Owen, F. E. Davies, J. A. Child, et al.
The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells
Blood,
December 1, 2000;
96(12):
3880 - 3886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, D. Chauhan, Y. Shima, N. Raje, F. E. Davies, Y.-T. Tai, S. P. Treon, B. Lin, R. L. Schlossman, P. Richardson, et al.
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
Blood,
November 1, 2000;
96(9):
2943 - 2950.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Kawamura, M. Kizaki, K. Yamato, H. Uchida, Y. Fukuchi, Y. Hattori, T. Koseki, T. Nishihara, and Y. Ikeda
Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3
Blood,
September 15, 2000;
96(6):
2005 - 2011.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ogawa, T. Nishiura, K. Oritani, H. Yoshida, M. Yoshimura, Y. Okajima, J. Ishikawa, K. Hashimoto, I. Matsumura, Y. Tomiyama, et al.
Cytokines Prevent Dexamethasone-induced Apoptosis via the Activation of Mitogen-activated Protein Kinase and Phosphatidylinositol 3-Kinase Pathways in a New Multiple Myeloma Cell Line
Cancer Res.,
August 1, 2000;
60(15):
4262 - 4269.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N. Raje and K. C. Anderson
Introduction: the evolving role of bisphosphonate therapy in multiple myeloma
Blood,
July 15, 2000;
96(2):
381 - 383.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Park, J. G. Seol, E. S. Kim, J. M. Hyun, C. W. Jung, C. C. Lee, B. K. Kim, and Y. Y. Lee
Arsenic Trioxide-mediated Growth Inhibition in MC/CAR Myeloma Cells via Cell Cycle Arrest in Association with Induction of Cyclin-dependent Kinase Inhibitor, p21, and Apoptosis
Cancer Res.,
June 1, 2000;
60(11):
3065 - 3071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Dankbar, T. Padro, R. Leo, B. Feldmann, M. Kropff, R. M. Mesters, H. Serve, W. E. Berdel, and J. Kienast
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
Blood,
April 15, 2000;
95(8):
2630 - 2636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hideshima, D. Chauhan, G. Teoh, N. Raje, S. P. Treon, Y.-T. Tai, Y. Shima, and K. C. Anderson
Characterization of Signaling Cascades Triggered by Human Interleukin-6 versus Kaposi's Sarcoma-associated Herpes Virus-encoded Viral Interleukin 6
Clin. Cancer Res.,
March 1, 2000;
6(3):
1180 - 1189.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. Teoh, Y.-T. Tai, M. Urashima, S. Shirahama, M. Matsuzaki, D. Chauhan, S. P. Treon, N. Raje, T. Hideshima, Y. Shima, et al.
CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines
Blood,
February 1, 2000;
95(3):
1039 - 1046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Tinhofer, I. Marschitz, T. Henn, A. Egle, and R. Greil
Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma
Blood,
January 15, 2000;
95(2):
610 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Oskeritzian, Z. Wang, J. P. Kochan, M. Grimes, Z. Du, H.-W. Chang, S. Grant, and L. B. Schwartz
Recombinant Human (rh)IL-4-Mediated Apoptosis and Recombinant Human IL-6-Mediated Protection of Recombinant Human Stem Cell Factor-Dependent Human Mast Cells Derived from Cord Blood Mononuclear Cell Progenitors
J. Immunol.,
November 1, 1999;
163(9):
5105 - 5115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Ruiter, S. F. Zerp, H. Bartelink, W. J. van Blitterswijk, and M. Verheij
Alkyl-Lysophospholipids Activate the SAPK/JNK Pathway and Enhance Radiation-induced Apoptosis
Cancer Res.,
May 1, 1999;
59(10):
2457 - 2463.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. M. van den Brink, R. Kapeller, J. C. Pratt, J.-H. Chang, and S. J. Burakoff
The Extracellular Signal-regulated Kinase Pathway Is Required for Activation-induced Cell Death of T Cells
J. Biol. Chem.,
April 16, 1999;
274(16):
11178 - 11185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. L. Ma, S. Kumar, F. Gao, C. S. Louden, B. L. Lopez, T. A. Christopher, C. Wang, J. C. Lee, G. Z. Feuerstein, and T.-L. Yue
Inhibition of p38 Mitogen-Activated Protein Kinase Decreases Cardiomyocyte Apoptosis and Improves Cardiac Function After Myocardial Ischemia and Reperfusion
Circulation,
April 6, 1999;
99(13):
1685 - 1691.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Rousselot, S. Labaume, J.-P. Marolleau, J. Larghero, M.-H. Noguera, J.-C. Brouet, and J.-P. Fermand
Arsenic Trioxide and Melarsoprol Induce Apoptosis in Plasma Cell Lines and in Plasma Cells from Myeloma Patients
Cancer Res.,
March 1, 1999;
59(5):
1041 - 1048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, T. Hideshima, S. Treon, G. Teoh, N. Raje, S. Yoshihimito, Y.-T. Tai, W. Li, J. Fan, J. DeCaprio, et al.
Functional Interaction between Retinoblastoma Protein and Stress-activated Protein Kinase in Multiple Myeloma Cells
Cancer Res.,
March 1, 1999;
59(6):
1192 - 1195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Sbih-Lammali, B. Clausse, H. Ardila-Osorio, R. Guerry, M. Talbot, S. Havouis, L. Ferradini, J. Bosq, T. Tursz, and P. Busson
Control of Apoptosis in Epstein Barr Virus-positive Nasopharyngeal Carcinoma Cells: Opposite Effects of CD95 and CD40 Stimulation
Cancer Res.,
February 1, 1999;
59(4):
924 - 930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Ayroldi, O. Zollo, L. Cannarile, F. D' Adamio, U. Grohmann, D. V. Delfino, and C. Riccardi
Interleukin-6 (IL-6) Prevents Activation-Induced Cell Death: IL-2-Independent Inhibition of Fas/fasL Expression and Cell Death
Blood,
December 1, 1998;
92(11):
4212 - 4219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Martins, T. J. Kottke, S. H. Kaufmann, and W. C. Earnshaw
Phosphorylated Forms of Activated Caspases Are Present in Cytosol From HL-60 Cells During Etoposide-Induced Apoptosis
Blood,
November 1, 1998;
92(9):
3042 - 3049.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Voorzanger-Rousselot, M.-C. Favrot, and J.-Y. Blay
Resistance to Cytotoxic Chemotherapy Induced by CD40 Ligand in Lymphoma Cells
Blood,
November 1, 1998;
92(9):
3381 - 3387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Spets, P. Georgii-Hemming, J. Siljason, K. Nilsson, and H. Jernberg-Wiklund
Fas/APO-1 (CD95)-Mediated Apoptosis Is Activated by Interferon-gamma and Interferon-alpha in Interleukin-6 (IL-6)-Dependent and IL-6-Independent Multiple Myeloma Cell Lines
Blood,
October 15, 1998;
92(8):
2914 - 2923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Treon, G. Teoh, M. Urashima, A. Ogata, D. Chauhan, I. J. Webb, and K. C. Anderson
Anti-Estrogens Induce Apoptosis of Multiple Myeloma Cells
Blood,
September 1, 1998;
92(5):
1749 - 1757.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Urashima, G. Teoh, D. Chauhan, A. Ogata, S. Shirahama, C. Kaihara, M. Matsuzaki, H. Matsushima, M. Akiyama, Y. Yuza, et al.
MDM2 Protein Overexpression Inhibits Apoptosis of TF-1 Granulocyte-Macrophage Colony-Stimulating Factor-Dependent Acute Myeloblastic Leukemia Cells
Blood,
August 1, 1998;
92(3):
959 - 967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-U. Simon, S. Yousefi, B. Dibbert, H. Hebestreit, M. Weber, D. R. Branch, K. Blaser, F. Levi-Schaffer, and G. P. Anderson
Role for Tyrosine Phosphorylation and Lyn Tyrosine Kinase in Fas Receptor-Mediated Apoptosis in Eosinophils
Blood,
July 15, 1998;
92(2):
547 - 557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F.-h. Xu, S. Sharma, A. Gardner, Y. Tu, A. Raitano, C. Sawyers, and A. Lichtenstein
Interleukin-6-Induced Inhibition of Multiple Myeloma Cell Apoptosis: Support for the Hypothesis That Protection Is Mediated Via Inhibition of the JNK/SAPK Pathway
Blood,
July 1, 1998;
92(1):
241 - 251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hebestreit, B. Dibbert, I. Balatti, D. Braun, A. Schapowal, K. Blaser, and H.-U. Simon
Disruption of Fas Receptor Signaling by Nitric Oxide in Eosinophils
J. Exp. Med.,
February 2, 1998;
187(3):
415 - 425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hallek, P. Leif Bergsagel, and K. C. Anderson
Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process
Blood,
January 1, 1998;
91(1):
3 - 21.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Chauhan, P. Pandey, A. Ogata, G. Teoh, N. Krett, R. Halgren, S. Rosen, D. Kufe, S. Kharbanda, and K. Anderson
Cytochrome c-dependent and -independent Induction of Apoptosis in Multiple Myeloma Cells
J. Biol. Chem.,
November 28, 1997;
272(48):
29995 - 29997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Urashima, J. A. DeCaprio, D. Chauhan, G. Teoh, A. Ogata, S. P. Treon, Y. Hoshi, and K. C. Anderson
p16INK4A Promotes Differentiation and Inhibits Apoptosis of JKB Acute Lymphoblastic Leukemia Cells
Blood,
November 15, 1997;
90(10):
4106 - 4115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Urashima, B. P. Chen, S. Chen, G. S. Pinkus, R. T. Bronson, D. A. Dedera, Y. Hoshi, G. Teoh, A. Ogata, S. P. Treon, et al.
The Development of a Model for the Homing of Multiple Myeloma Cells to Human Bone Marrow
Blood,
July 15, 1997;
90(2):
754 - 765.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Vincent, M. Jourdan, M.-S. Sy, B. Klein, and N. Mechti
Hyaluronic Acid Induces Survival and Proliferation of Human Myeloma Cells through an Interleukin-6-mediated Pathway Involving the Phosphorylation of Retinoblastoma Protein
J. Biol. Chem.,
April 27, 2001;
276(18):
14728 - 14736.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
